Literature DB >> 3312267

Potential use of serotherapy in the prevention and treatment of infection with the human immunodeficiency virus.

S Zolla-Pazner1, A Pinter, H Mizuma.   

Abstract

While prevention of infection with the human immunodeficiency virus (HIV) using prophylactic immunization and treatment with anti-viral drugs would appear to be the methods of choice for the prevention and treatment of this infection, neither safe and effective vaccines nor anti-viral agents have yet been developed. A third approach should thus be considered which could be employed both for prophylaxis and treatment of this disease. This approach utilizes specific, anti-HIV antibodies, passively administered, to prevent and/or slow the infectious process. The disadvantages of using xenogeneic antibodies and the advantages of using human antibodies are discussed. The need for large quantities of human antibodies to HIV necessitates the production of cell lines producing these antibodies. The various techniques of producing these lines are summarized. Finally, preliminary data supporting the feasibility of producing human cell lines producing antibody to HIV are presented.

Entities:  

Mesh:

Year:  1987        PMID: 3312267     DOI: 10.1016/0166-0934(87)90067-x

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  8 in total

1.  Molecular characterization of five human anti-human immunodeficiency virus type 1 antibody heavy chains reveals extensive somatic mutation typical of an antigen-driven immune response.

Authors:  J S Andris; S Johnson; S Zolla-Pazner; J D Capra
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

Review 2.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

Review 3.  Immunity to retroviral infection: the Friend virus model.

Authors:  K J Hasenkrug; B Chesebro
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

4.  Secretion of Toxoplasma gondii-specific antibody in vitro by peripheral blood mononuclear cells as a new marker of acute toxoplasmosis.

Authors:  J P Vendrell; F Pratlong; A Decoster; P Boulot; A M Conge; F Darcy; M Segondy; M F Huguet; A Serre
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

5.  Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness.

Authors:  K J Hasenkrug; D M Brooks; B Chesebro
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

6.  Generation of human monoclonal antibodies to human immunodeficiency virus.

Authors:  M K Gorny; V Gianakakos; S Sharpe; S Zolla-Pazner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

Review 7.  Antiviral therapy in human immunodeficiency virus infection.

Authors:  E Sandström
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

8.  Biological response modifiers and infectious diseases: actual and potential therapeutic agents.

Authors:  J J Rusthoven
Journal:  Int J Antimicrob Agents       Date:  1994       Impact factor: 5.283

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.